Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery

Clin Hemorheol Microcirc. 2017;66(1):57-66. doi: 10.3233/CH-160216.

Abstract

To evaluate the parameters of the thrombin generation test (TGT) in coronary artery disease (CAD) patients on prolonged aspirin therapy during on-pump coronary artery bypass grafting (CABG) after donor platelet concentrate transfusion. A total of 148 patients with CAD on prolonged aspirin therapy (75-100 mg/day) who have undergone elective on-pump CABG were consecutively included in the study. Patients were divided randomly into two groups. Group 1 (n = 76) received donor platelet transfusions after cardiopulmonary bypass, whereas Group 2 (n = 72) did not. TGT parameters were measured using an analyzer at pre-, intra-, and early postoperative periods. Activation of the endogenous thrombin potential was observed in patients on prolonged aspirin therapy in the pre- and intraoperative periods, as confirmed by high peak thrombin and increased velocity index. The activation time of the prothrombinase complex and thrombin generation time were greater than the control group. The blood hemostatic potential in patients who did not receive transfusions in the early postoperative period decreased up to the level of the control group in the extended time parameters. Hemostatic potential in plasma in patients on aspirin was preserved. Given the laboratory test results and clinical data, platelet concentrate transfusion is unnecessary for prevention.

Keywords: Thrombin generation test; aspirin therapy; coronary artery disease; platelet transfusion.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Aspirin / therapeutic use*
  • Blood Coagulation Tests / methods*
  • Coronary Artery Bypass / methods*
  • Female
  • Hemostasis / physiology*
  • Humans
  • Male
  • Middle Aged
  • Platelet Transfusion / methods*
  • Thrombin / therapeutic use*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Thrombin
  • Aspirin